Test Directory

Home Test Search Results Factor VIII (8) Inhibitor Titer – Chromogenic (Nijmegen-modified Bethesda assay)
Factor VIII (8) Inhibitor Titer – Chromogenic (Nijmegen-modified Bethesda assay)

Justification

Acquired factor deficiencies may occur due to the development of factor-specific inhibitory antibodies. These antibodies may also develop against factor replacement products in patients with a congenital deficiency. This test may be used to detect and quantitate inhibitory antibodies against Factor VIII. This assay is suitable for the detection of Factor VIII inhibitors in patients on the recombinant, monoclonal antibody treatment Hemlibra (emicizumab).

STAT: < 24 hours (M-F)

Bethesda, Chromogenic

Draw Tube: Blue Top

Sample Type: Citrated Plasma

Specimen Requirements

Sample Type Volume Required Minimum Volume Stability
PREFERRED Citrated Plasma Two aliquots, 1mL each Two aliquots, 0.5mL each Room Temp.: 2 hours
Refrigerated: 2 hours
Frozen (-20C): 2 weeks
Frozen (-80C): 6 months
ALTERNATIVE - - - -
REJECTION CRITERIA Thawed in transit, refrozen or clotted sample
SPECIAL INSTRUCTIONS -

General Information

METHODOLOGY Bethesda, Chromogenic
STAT TAT < 24 hours (M-F)
STAT TAT Performance > 90% of results released in 24 hours
ROUTINE TAT < 3 days (M-F)
ALTERNATIVE NAMES Chromogenic Factor VIII (8) Inhibitor Titer, Factor VIII (8) Inhibitor Titer - Hemlibra specific, F8 chromogenic inhibitor, FVIII chromogenic inhibitor
DESCRIPTION Nijmegen-modified Bethesda titer for the quantitative determination of a specific factor inhibitor against factor VIII (8).
LIMITATIONS -
NORMAL RANGE < 0.4 NBU
ASSOCIATED TESTING -
REFERENCES -
SAMPLE REPORT Upon request
NEW YORK STATE APPROVED -

Test Codes

ORDER CODE P3383
CPT CODE 85240, 85335
LOINC CODE 3204-5, 3209-4